文献速递类风湿关节炎

巴瑞替尼治疗生物制剂应答不佳类风湿关节炎患者的患者报告结局:III期随机研究RA-BEACON

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
PubMed 文献 · Ann Rheum Dis · 2016-10-31

这项双盲III期研究纳入527例对至少一种TNF抑制剂或其他bDMARDs应答不足或不耐受的活动性类风湿关节炎患者,随机接受安慰剂或巴瑞替尼2 mg或4 mg每日一次治疗24周。巴瑞替尼组在多数患者报告结局上较安慰剂显著改善,4 mg组改善通常更迅速且幅度更大,并维持至第24周。

要点

  • 巴瑞替尼2 mg和4 mg组在多数PROs上较安慰剂显著改善。
  • 4 mg组改善通常更迅速、幅度更大,并维持至第24周。
  • 第24周时巴瑞替尼组达到HAQ-DI<0.5、FACIT-F≥3.56等应答的患者比例显著高于安慰剂。

核心结论

  • 在对bDMARDs(包括至少一种TNFi)应答不足的难治性类风湿关节炎患者中,巴瑞替尼治疗24周可改善多数患者报告结局。

研究设计与样本

  • 双盲III期随机对照研究,527例患者随机分配至安慰剂(176例)、巴瑞替尼2 mg(174例)或巴瑞替尼4 mg(177例),每日一次治疗24周。

主要发现

  • 巴瑞替尼两个剂量组在多数PROs上较安慰剂显示统计学显著改善。
  • 巴瑞替尼4 mg组的改善通常比2 mg组更迅速且幅度更大,并维持至第24周。
  • 第24周时,巴瑞替尼组较安慰剂组更多患者报告正常躯体功能(HAQ-DI<0.5;p≤0.001)。
  • 第24周时,巴瑞替尼组较安慰剂组更多患者报告疲劳减轻(FACIT-F≥3.56;p≤0.05)、PtGA改善(p≤0.001)、疼痛改善(p≤0.001)和晨僵持续时间缩短(p<0.01)。

关键数值与推荐

  • 正常躯体功能定义为HAQ-DI<0.5,第24周巴瑞替尼组达到该标准的患者比例显著高于安慰剂组(p≤0.001)。
  • 疲劳减轻定义为FACIT-F改善≥3.56,第24周巴瑞替尼组达到该标准的患者比例显著高于安慰剂组(p≤0.05)。
  • 第24周巴瑞替尼组PtGA改善和疼痛改善均显著优于安慰剂(p≤0.001),晨僵持续时间缩短亦显著优于安慰剂(p<0.01)。

临床怎么用

  • 对于既往bDMARDs应答不足的难治性类风湿关节炎患者,巴瑞替尼可改善躯体功能、疲劳、患者总体评估、疼痛和晨僵等患者报告结局。
  • 巴瑞替尼4 mg在患者报告结局上的改善通常比2 mg更迅速且幅度更大,临床决策时需结合患者具体情况权衡剂量选择。

局限性

  • 研究仅报告24周内的患者报告结局,未提供更长疗程的数据。
  • 原文未报告PROs分析中具体缺失数据的处理方式及亚组分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs). METHODS: In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables. RESULTS: 527 patients were randomised (placebo, 176; baricitinib 2 mg, 174; baricitinib 4 mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4 mg than 2 mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI <0.5; p≤0.001), reductions in fatigue (FACIT-F ≥3.56; p≤0.05), improvements in PtGA (p≤0.001) and pain (p≤0.001) and reductions in duration of MJS (p<0.01). CONCLUSIONS: Baricitinib improved most PROs through 24 weeks compared with placebo in this study of treatment-refractory patients with previously inadequate responses to bDMARDs, including at least one TNFi. PRO results aligned with clinical efficacy data for baricitinib. TRIAL REGISTRATION NUMBER: NCT01721044; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2016. PMID: 27799159. doi:10.1136/annrheumdis-2016-209821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。